School of Medicine


Showing 1-19 of 19 Results

  • Steven Sanislo, MD

    Steven Sanislo, MD

    Clinical Professor, Ophthalmology

    Bio Dr Sanislo has over 20 years of experience in clinical and surgical practice in retinal and vitreoretinal diseases. He is the senior vitreoretinal surgeon at Stanford and maintains a large clinical practice as well as teaching ophthalmology residents and retina fellows. He also participates in clincal reasearch for varying retinal conditions. Dr. Sanislo recieved ophthalmology training as a resident here at Stanford, and recieved vitreoretinal training as a fellow at the Cleveland Clinic Foundation.

    Research interests include treatment of age-related macular degeneration, diabetic retinopathy and other retinal diseases.

    Dr. Sanislo has extensive clinical and surgical experience in the following diseases:
    - Age-related macular degeneration
    - Posterior uveitis / infectious and inflammatory disease of the posterior segment
    - Diabetic retinopathy
    - Myopic degeneration / pathologic myopia
    - Macular pucker / epiretinal membranes
    - Macular hole
    - Repair of simple and complex retinal detachments
    - Macular edema
    - Retinal vascular occlusion

  • Ira Schachar, MD, MSc

    Ira Schachar, MD, MSc

    Assistant Professor of Ophthalmology at the Stanford University Medical Center

    Bio Dr. Schachar is a board-certified ophthalmologist and vitreoretinal surgeon. He spends his clinical time helping the underserved population at Santa Clara Valley Medical Center. It is there that Dr. Schachar treats some of the most challenging conditions facing ophthalmologists today. He has expertise in the areas of ocular complications of diabetes, retinal detachments, and uveitis. In addition to his adult patients, Dr. Schachar screens and treats premature infants at Lucile Packard Children?s Hospital who are at risk for retinopathy for prematurity. His overarching goal is to capitalize on the most advanced surgical techniques, laser treatments, and drug therapies to minimize patient discomfort, accelerate healing, and maximize long-term outcomes.

    When Dr. Schachar is not seeing patients, he is working to advance the field of ophthalmology through translational research. His basic science research is primarily dedicated towards mechanisms to increase the duration of action and enhance the effectiveness of antibodies, such as Avastin, Lucentis, and Eylea, which are injected into the eye. Separately, he is refining surgical implants for the treatment of presbyopia and is a co-founder and board member of Vitrean, Inc., a pharmaceutical company developing novel treatments for retinal detachments.

    Biography:
    Dr. Schachar graduated Summa Cum Laude with a Bachelor of Science in Mathematics from Duke University. From there he traveled to Oxford, where he received a master?s degree in biology. He attended the premier Washington University School of Medicine in St. Louis where he was inducted into the AOA Honor Medical Society. After graduating from medical school, he went on to complete his Medical Internship at the prestigious Brigham and Women?s Hospital in Boston and then completed his Ophthalmology residency at the world renown University of Michigan in Ann Arbor. During residency, he received numerous awards related to teaching, research, and clinical expertise. He then completed his fellowship training in vitreoretinal surgery at Stanford University.

    In addition to these accomplishments, Dr. Schachar has an appreciation for underappreciated hobbies. Some of his favorites are card magic, juggling, yo-yoing, and collecting insects.

  • Ann Shue, MD

    Ann Shue, MD

    Clinical Assistant Professor, Ophthalmology

    Bio **Dr. Shue is taking new patients for glaucoma, cataracts, and adult strabismus.**

    Ann Shue, MD, is a Clinical Assistant Professor of Ophthalmology at Stanford University School of Medicine, where she specializes in glaucoma, pediatric ophthalmology, and adult strabismus, a unique combination of subspecializations practiced by few surgeons worldwide. She is a board-certified ophthalmologist who completed fellowships in glaucoma at Yale University and pediatric ophthalmology and adult strabismus at Duke University. She practices at the Stanford Byers Eye Institute and the Lucile Packard Children's Hospital.

    Dr. Shue loves seeing patients of all ages with eye problems big or small, including glaucoma due to any reason, glaucoma suspicion, family history of glaucoma, cataracts, strabismus (eye misalignment) or double vision from any cause, including after eye surgeries. She completed her ophthalmology residency at the University of Pittsburgh and an internal medicine internship at UCSF Fresno. She holds a medical degree from University of California, Irvine and an undergraduate degree in biology from Yale University.

    Dr. Shue is a member of the American Glaucoma Society, the American Association for Pediatric Ophthalmology and Strabismus, and the UK Paediatric Glaucoma Society. She is active in presenting at regional and national conferences. She is the author of several journal articles and recently wrote two textbook chapters on pediatric glaucoma and pediatric glaucoma surgery.

  • Ruwan Silva, MD, MPhil

    Ruwan Silva, MD, MPhil

    Clinical Assistant Professor, Ophthalmology

    Bio Professor Ruwan Amila Silva, MD, MPhil is board certified and fellowship trained vitreoretinal surgeon in the department of ophthalmology at Stanford University Medical Center. He received his BA in Neurobiology from Harvard University graduating Magna cum laude with Highest Honors. He then received his Masters of Philosophy (MPhil) in Neurobiology from Cambridge University in England. Following this, he received his medical degree from Stanford University?s School of Medicine. Dr. Silva completed his ophthalmology residency at the Bascom Palmer Eye Institute, the top rated eye hospital in the country. While there he was awarded the Heed Fellowship, the most prestigious national award for ophthalmology residents in the country. Dr. Silva returned to Stanford University to complete his vitreoretinal surgery fellowship where he was awarded the Ronald G. Michels Foundation Award, the nation?s highest honor for a retina surgery fellow. During his fellowship at Stanford he was also awarded the prestigious Evangelos S. Gragoudas Award by the Macula Society. Following fellowship, Dr. Silva remained at Stanford University's School of Medicine as an Assistant Professor of Vitreoretinal Surgery in the Department of Ophthalmology. Since 2015, he has been named one of ?America?s Top Ophthalmologists? by Consumers? Research Council of America. He was also selected as a "Top Ophthalmologist" by the International Association of Ophthalmologists.

    Dr. Silva's clinical practice focuses mainly on macular degeneration and retinal vascular disease (such as diabetic retinopathy, retinal vein occlusions and central serous retinopathy). Surgically, he specializes in diseases of the vitreous and retina: including repair of retinal detachments, surgery for the macula (such as treatment of epiretinal membranes and macular holes) and correction of dislocated intraocular lenses. His research interests mainly involve developing novel therapies for these diseases (http://med.stanford.edu/artificial-retina.html) and have resulted in over 50 combined peer-reviewed scientific manuscripts, book chapters and national meeting presentations.

    Dr. Silva is a member of the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology, as well as the American Society of Retina Specialists. He is a Board Certified Diplomate of the American Board of Ophthalmology.

  • Kuldev Singh, MD, MPH

    Kuldev Singh, MD, MPH

    Professor of Ophthalmology at the Stanford University Medical Center

    Current Research and Scholarly Interests Glaucoma, clinical epidemiology

  • Stephen Smith, MD

    Stephen Smith, MD

    Clinical Instructor (Affiliated) [Vapahcs], Ophthalmology

    Current Research and Scholarly Interests RESEARCH OVERVIEW

    Dr. Smith?s primary professional interest is developing solutions for unmet clinical and surgical vitreoretinal needs. Beginning in medical school, one of his primary focuses has been improving treatment outcomes in patients with retinoblastoma (RB). During his second year in medical school Dr. Smith published a manuscript on a novel technique to reduce the risk of tumor spread following intravitreal drug delivery in patients with RB. His work summarizing published data on tumor spread following intravitreal injection therapy (IVT) for RB has resulted in multiple platform presentations at national and international meetings, including an invited lecture at ARVO 2014. The results of this study influenced the growing trend toward broader acceptance of intravitreal chemotherapy in pediatric patients with treatment-resistant retinoblastoma vitreous seeds. A primary active area of research has included studying and publishing on ocular toxicity that results from the use of intravitreal melphalan and other agents for RB. This work, and subsequent publications from leaders in the field, has led to an increased awareness of ocular toxicity caused by injecting chemotherapeutic agents into the eyes of young children. This highlighted the need for toxicity data on additional chemotherapeutic agents for local delivery. To answer this question, Dr. Smith assembled an excellent group of collaborators and consultants, including internationally known experts at Bascom Palmer, Mayo Clinic, and Emory University. As a resident he secured a highly competitive career starter grant from the Knights Templar Foundation and used that funding and the expertise of his collaborators to carry out preclinical ocular toxicity studies of combination intravitreal chemotherapy for RB. His work in RB has led to a broader recognition of the challenges facing patients with RB who receive IVT and has led to a continued search for optimal local injectable therapies for patients with this disease.


    INNOVATION HIGHLIGHTS

    In addition to his work in retinoblastoma, Dr. Smith has been actively involved in developing technologies to improve outcomes for patients receiving intravitreal injection therapy (IVT) for macular degeneration, diabetic retinopathy, retinal vein occlusions and more. IVT has become the most common procedure performed by retina specialists in the United States, with an estimated 6 million injections given in the United States alone in 2016. Dr. Smith has co-developed technology that simplifies and streamlines the IVT process, removing barriers to treatment and improving patient outcomes. His work in innovation covers pre-clinical and clinical development work, and has given him expertise in diverse subject areas including fundraising, intellectual property portfolio development, team building, and business administration. He is a co-founder of iRenix Medical, a biotechnology and medical device start-up company committed to improving vision through optimization of the IVT process.

    Dr. Smith remains dedicated to helping improve and restore vision and quality of life in patients with vitreoretinal disease. He is currently involved in both medical device and pharmaceutical innovation, and serves as a mentor for the Stanford University Biodesign Innovation Course.

  • Creed Stary

    Creed Stary

    Associate Professor of Anesthesiology, Perioperative and Pain Medicine (Adult MSD) and, by courtesy, of Ophthalmology at the Stanford University Medical Center

    Current Research and Scholarly Interests Mechanisms promoting neuronal survival following cerebral ischemia-reperfusion injury; utilizing microRNA's to target multiple pathways to promote mitochondrial homeostasis and cell survival; anesthetic neurotoxicity; astrocyte-neuronal interaction

  • Yang Sun, MD, PhD

    Yang Sun, MD, PhD

    Associate Professor of Ophthalmology at the Stanford University Medical Center

    Current Research and Scholarly Interests We are interested in the role of inositol phosphatases in eye development and disease, using both animal models and human disease tissue. We are a translational laboratory seeking to understand the basic function of proteins as well as developing therapeutic strategies for clinical trials.

Footer Links:

Stanford Medicine Resources: